$ELOX News

Last published 1w ago

1w agoELOXEloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKDPR NewswireFDA clearance of the IND enables Eloxx to open U.S. clinical sites for EXPRESS, its global Phase 2 study of exaluren in nonsense-mutation ADPKDEXPRESS will randomize approximately 60 patients 1:1 to exaluren or placebo
3w agoELOXEloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical OfficerPR NewswireEXPRESS Phase 2 design finalized: 52 weeks of dosing of approximately 60 patients randomized 1:1 to exaluren or placebo, with annualized htTKV growth as the primary endpointSubstantial, durable htTKV effect could
3w agoELOXEloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of DirectorsPR NewswireMr. Germano brings more than 35 years of biopharmaceutical leadership experience, including as Group President of Pfizer's Global Innovative Pharmaceutical businessExtensive public company board experience,
2mo agoELOXEloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport SyndromePR NewswireEloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, ...
3mo agoELOXEloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business UpdatePR NewswireCompleted underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheetPhase 2b clinical trial of exaluren in
5mo agoELOXEloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to NasdaqPR NewswireEloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule...
3y agoATAI ATOS ELOXCognito Therapeutics Appoints Greg Weaver as Chief Financial OfficerBusiness WireCognito Therapeutics, a pioneer developing disease-modifying therapeutics to treat CNS diseases, today announced the appointment of Greg Weaver as Chief Financial Officer (CFO), to lead all finance-related and investor
3y agoELOXEloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaGlobeNewswireELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH Biopsy results support clinical benefit in all three
3y agoELOXEloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireWATERTOWN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a
3y agoELOXEloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeGlobeNewswireHighly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three patients treated with
3y agoELOXEloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013GlobeNewswireInvestigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations Rebound in average UPCR 3-months post treatment
3y agoELOXEloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business UpdateGlobeNewswireAnnounced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the
3y agoELOXEloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeGlobeNewswireAll three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying
3y agoELOXEloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing RequirementGlobeNewswireWATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the
3y agoELOXEloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic BenefitGlobeNewswirePublication titled "A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer" published in Cancer Research Communications
3y agoELOXEloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02GlobeNewswireAlport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available Eloxx
3y agoELOXEloxx Pharmaceuticals to Host Investor and Analyst Call on Alport SyndromeGlobeNewswireGlobally renowned Alport syndrome experts will provide key insights Eloxx recently announced achievement of remission in one patient in its Phase 2 Alport syndrome clinical study and decision to advance into a pivotal
3y agoELOXEloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA CongressGlobeNewswireData from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney failure Patient that achieved
3y agoELOXEloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) PatientsGlobeNewswireELX-02 trial results demonstrated clinically relevant improvement in percent predicted forced expiratory volume (ppFEV1) based on final data assessment; initial topline results were previously reported in September
3y agoELOXEloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing RequirementGlobeNewswireWATERTOWN, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Nasdaq Hearings Panel has
3y agoATAI ATOS ELOXAtossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial OfficerGlobeNewswireSEATTLE, June 01, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology
3y agoELOXEloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 StudyGlobeNewswirePatient treated in trial achieved a remission after eight weeks of treatment, demonstrating a significant reduction in proteinuria ELX-02 well-tolerated in study, with no discontinuations to date WATERTOWN, Mass., May
3y agoELOXEloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateGlobeNewswireTopline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in
3y agoELOXEloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013GlobeNewswireZKN-013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa (RDEB and JEB) and Familial Adenomatous Polyposis (FAP) ZKN-013 is Eloxx's first drug candidate from its
3y agoELOXEloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business UpdateGlobeNewswireThree patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction in proteinuria has been observed in one patient to date Investigational New Drug
3y agoELOXEloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013GlobeNewswireZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) Additional IND filing for ZKN-013 for treatment of familial adenomatous polyposis
3y agoELOXEloxx Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewswireWATERTOWN, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it will present at the
3y agoELOXEloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient DosedGlobeNewswireWATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now
3y agoELOXEloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport SyndromeGlobeNewswireTopline results expected in first half of 2023 Trial sites open in Australia and United Kingdom WATERTOWN, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal
3y agoELOXEloxx Pharmaceuticals Announces Reverse Stock Split EffectiveGlobeNewswireWATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (the "Company") (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that its Board of
4y agoELOXEloxx Pharmaceuticals Reports Third Quarter 2022 Financial and Operating Results and Provides Business UpdateGlobeNewswireStarted proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results expected in the first half of 2023 On track to submit IND application for
4y agoELOXEloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport SyndromeGlobeNewswireWATERTOWN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the opening of clinical trial sites
4y agoELOXEloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) PatientsGlobeNewswireCombination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity fo
4y agoELOXEloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business UpdateGlobeNewswireTopline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022 On track to initiate a proof-of-concept clinical trial with ELX-02 in up to eight Alport syn
4y agoELOXA Study of ELX-02 in Patients With Alport Syndrome - NCT05448755ClinicalTrials.govThe incidence and characteristics of adverse events, Change in proteinuria, Change in Col IV expression in renal biopsy, Change in hematuria
4y agoELOXEloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business UpdateGlobeNewswireCystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected at the end
4y agoELOXEloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business UpdateGlobeNewswireExpect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million
4y agoELOXEloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport SyndromeGlobeNewswireStrong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially transported to kidney Initiation of proof-of-concept clinical trial expe
4y agoELOXEloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis FoundationGlobeNewswireCystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program Expect topline data from cystic fibrosis Phase 2 expansion treatment arms evaluating combination with ivacaftor by the en
4y agoELOXEloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis PatientsGlobeNewswireELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 in
5y agoELOXEloxx Pharmaceuticals Reports Third Quarter 2021 Financial and Operating Results and Provides Business UpdateGlobeNewswireData from Monotherapy Arms of Ongoing Phase 2 ELX-02 Cystic Fibrosis (CF) Clinical Trials Expected in Fourth Quarter of 2021 Received FDA Fast Track Designation for ELX-02 for the Treatment of CF Patients with Nonsense Mutations
5y agoELOXEloxx Pharmaceuticals to Host Investor and Analyst Call and Webcast on Cystic Fibrosis ProgramsGlobeNewswireGlobally renowned CF Expert, Dr. Eitan Kerem will provide key insights Data from ongoing Phase 2 trials in CF expected in 4Q 2021 WATERTOWN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), today announced that
5y agoELOX HTGCEloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules CapitalGlobeNewswireWATERTOWN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), today announced that the company has entered into a debt facility of up to $30.0 million with Hercules Capital, Inc. (NYSE:HTGC), a specialty financing lende
5y agoBVAXF ELOX LIFE LPTX+1Why Pharmaceutical Companies in Ovarian Cancer Drugs Market are Betting Big on R&DPR NewswirePALM BEACH, Fla., Sept. 17, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - The ovarian cancer drugs market consists of sales of ovarian cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in ovary
5y agoELOXEloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense MutationsGlobeNewswireWATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02, a drug candidate intended to treat cystic fi
5y agoELOXEloxx Pharmaceuticals Appoints Chief Medical OfficerGlobeNewswireWATERTOWN, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), today announced the appointment of Ali Hariri, M.D., as its Chief Medical Officer, overseeing clinical development efforts for the company's promising pipel
5y agoELOXEloxx Pharmaceuticals Reports Second Quarter 2021 Financial and Operating Results and Provides Business UpdateGlobeNewswireAdded Additional Treatment Arm and Provided Enrollment Update for Ongoing ELX-02 Phase 2 Clinical Trials for Cystic Fibrosis (CF) Nominated ZKN-013 as Lead Candidate for Recessive Dystrophic Epidermolysis Bullosa (RDEB) and Junctional Epidermolysis Bu
5y agoELOX HOPHFHemogenyx Pharmaceuticals PLC Announces Appointment of Business Advisor & Board ObserverACCESS NewswireDr Alan E. Walts joins Hemogenyx Pharmaceuticals team; renowned business leader brings industry experience in corporate and private venture capital, business development, R&D and general management. LONDON, UK / ACCESSWIRE / July 26, 2021 / Hemogenyx Ph
5y agoELOXEloxx Pharmaceuticals Provides Enrollment Update for Ongoing Phase 2 Clinical Studies for Cystic FibrosisGlobeNewswireWATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for ELX-02 for the treatment of cystic fibrosis (CF) in patients with
5y agoAVIR DARE ELOX PBTS+1Thinking about buying stock in Dare Bioscience, Powerbridge Technologies, Atea Pharmaceuticals, Ammo Inc, or Eloxx Pharmaceuticals?PR NewswireNEW YORK, June 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, PBTS, AVIR, POWW, and ELOX.